特发性膜性肾病免疫抑制治疗的最新进展

Advanced progress in immunosuppressive therapy for idiopathic membranous nephropathy

特发性膜性肾病(idiopathic membranous nephropathy,IMN)是肾病综合征最常见的病因之一,发病率逐年增加,30%~40%的IMN患者有持续性尿蛋白,并逐渐进展为终末期肾病,严重影响人们的健康。近几年各类新型免疫抑制剂投入临床使用,如新型单克隆抗体、蛋白酶体抑制剂、补体抑制剂,为IMN治疗提供了新的治疗方案。

Idiopathic membranous nephropathy(IMN)is one of the most common causes of nephrotic syndrome,and its incidence rate is increasing year by year.There are 30%–40%of IMN patients with persistent urinary protein which can develop to an end-stage renal disease,so it seriously affects people’s health.In recent years,various new immunosuppressive agents have been introduced into clinic,such as new monoclonal antibodies,proteasome inhibitors,complement inhibitor,has provided a new treatment regimen for IMN.